Effective Treatment of Diabetes Mellitus by Resonance Medicine.

The metabolic disorder known as diabetes mellitus (DM) has several different causes, distinguished by recurring hyperglycemia due to inadequate insulin secretion, insulin action, or both. T-lymphocytes target such cells for destruction, which include beta cells. Transplants of the pancreas, islets of Langerhans, and individual beta cells are all effective treatments for DM. Additionally, treating DM using stem cells is popular currently. The basis of stem cell therapy for DM is the replacement of beta cells, or dead pancreatic cells, with stem cells. After attaching to the tissues of the pancreas, the stem cells differentiate into active cells. An X-ray scanner is used to place a catheter into the pancreatic artery in DM, and the process lasts 90 minutes. The use of stem cells to replace dead pancreatic beta cells forms the cornerstone of stem cell treatment for DM. Transplants of the pancreas, islets of Langerhans, and individual beta cells are all effective treatments for insulin-dependent DM. In contrast to prior studies, where we only used low potencies of nosodes and organopreparations, our research used both high and low potencies of these substances. Choosing the strength of the nosode stomach cancer in the computer-connected device selector so that it will resonate with the nosode that is tested in the patient's device is the doctor's responsibility when using the bioresonance therapy method. The initial nosode, which is in the computer programme of the device for bioresonance therapy, is no longer tested when the stomach cancer nosode is tested in a patient along with the chosen potency of this nosode. The initial nosode in the bioresonance therapy device itself is still being studied in case the chosen nosode's potency is inadequate (the frequency of oscillations of the nosode is lower than the frequency of oscillations of the tumour).

Safety and Evaluation of the Immune Response of Coronavirus Nosode (BiosimCovex) in Healthy Volunteers: A Preliminary Study Extending the Homeopathic Pathogenetic Trial.

Objectives: Regulatory clinical Phase I studies are aimed at establishing the human safety of an active pharmaceutical agent to be later marketed as a drug. Since homeopathic medicines are prepared by a potentizing method using alcohol, past a certain dilution, their toxicity/infectivity is assumed to be unlikely. We aimed to develop a bridge study between homeopathic pathogenetic trials and clinical trials. The primary purpose was to evaluate the safety of a nosode, developed from clinical samples of a COVID-19 patient. The secondary objectives were to explore whether a nosode developed for a specific clinical purpose, such as use during an epidemic, may elicit laboratory signals worthy of further exploration. Methods: An open-label study was designed to evaluate the safety and immune response of the Coronavirus nosode BiosimCovex, given orally on three consecutive days to ten healthy volunteers. Clinical examinations, laboratory safety and immune parameters were established. Interferon-gamma, Interleukin-6, and CD 4 were measured. (CTRI registration number: CTRI/2020/05/025496). Results: No serious/fatal adverse events were reported. Laboratory tests to measure safety were unchanged. Three subjects showed elevated Interleukin-6 (IL-6) on day 17 in comparison to the baseline, and ten subjects showed elevated IL-6 on day 34. A significant difference between IL-6 observations, calculated by repeated measures ANOVA, was found to be highly significant. On day 60, the IL-6 values of nine subjects were found to return to normal. Corresponding CD4 cell elevation was observed on day 60, when compared to day 34. Conclusions: HPT may potentially extend into physiological changes with regards to immune response and should encourage future studies.

Antifungal activity of homeopathic medicines against the white mold causing agent Sclerotinia sclerotiorum

White mold disease, caused by fungus Sclerotinia sclerotiorum (Lib.) de Bary., is a disease hard to control due to the high amount of sclerotia produced, which guarantees its survival in the soil for years leading to significant yield losses. Alternative techniques to control the pathogen have been researched, including homeopathy. The present work aimed to evaluate the in vitro antifungal effect of homeopathic medicines on S. sclerotiorum mycelial growth. Homeopathic medicines Sulphur, fungal sclerotium Nosode and Calcarea carbonica, in 30CH, 200CH and 1000CH dynamizations were tested. Assays were carried out in a completely randomized design, with four repetitions. Experiments were performed through the addition of homeopathic medicines on the surface of plates containing culture medium, followed by insertion of a disc containing fungus mycelia and incubation. Control treatment received no homeopathic medicine. The mycelial progression was monitored by seven halo diameter measurements during experiment period. All homeopathic medicines tested and their dynamizations were able to inhibit partially the development of the fungus. Calcarea carbonica at the dynamization of 1000 CH showed the best inhibitory effect on S. sclerotiorum, which under its effect produced a mycelial halo 40% smaller than the control treatment.

Therapeutic potential of HIV nosode 30c as evaluated in A549 lung cancer cells.

OBJECTIVES: To examine if HIV nosode in 30c dilution (HIV 30c) has therapeutic potential against lung cancer cells (A549) as compared to WRL-68 normal cells and to elucidate its possible molecular mechanism of action on DNA replication and apoptosis. METHODS: Effects of HIV 30c were thoroughly tested for its possible anticancer potential on A549 cells (lung cancer); WRL-68 normal liver cells served as control. Three doses, one at LD50 and two below LD-50, were used. Proliferation, migration and senescence assays were made and generation of reactive oxygen species (ROS) studied by routine techniques. The ability of HIV 30c to induce apoptosis in A549 cells and its possible signalling pathway were determined using immunoblots of relevant signal proteins and confocal microscopy, including studies on telomerase reverse transcriptase (TERT) and topoisomerase II (Top II) activities, intimately associated with cell division and DNA replication. RESULTS: HIV 30c prevented cancer cell proliferation and migration, induced pre-mature senescence, enhanced pro-apoptotic signal proteins like p53, bax, cytochrome c, caspase-3 and inhibited anti-apoptotic signal proteins Bcl2, TERT and Top II, changed mitochondrial membrane potential and caused externalization of phosphatidyl serine. Thus, it induced apoptosis as also evidenced from increase in cells with distorted membrane morphology, nuclear condensation, DNA fragmentation, and ROS, typical of apoptosis in progress. CONCLUSION: HIV 30c nosode has therapeutic potential for inducing cytotoxic effects on A549 cells as manifested by changes in nuclear condensation, DNA fragmentation, ROS generation and MMP, and for its inhibitory action on cell proliferation, cell migration, expression of telomerase reverse transcriptase and Top II genes, and increasing expression of pro-apoptotic genes.

Action of antibiotic oxacillin on in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) previously treated with homeopathic medicines.

BACKGROUND: Resistance to antibiotics is a major public health concern worldwide. New treatment options are needed and homeopathy is one such option. We sought to assess the effect of the homeopathic medicine Belladonna (Bell) and a nosode (biotherapy) prepared from a multi-drug resistant bacterial species, methicillin-resistant Staphylococcus aureus (MRSA), on the same bacterium. METHODS: Bell and MRSA nosode were prepared in 6cH and 30cH potencies in 30% alcohol and sterile water, according to the Brazilian Homeopathic Pharmacopeia and tested on MRSA National Collection of Type Cultures (NCTC) 10442. We assessed in vitro bacterial growth, deoxyribonuclease (DNAase) and hemolysin activity, and in vitro bacterial growth in combination with oxacillin (minimum inhibitory concentration - MIC). All values were compared to control: 30% alcohol and water. RESULTS: In vitro growth of MRSA was statistically significantly inhibited in the presence of Bell and nosode 6cH and 30cH compared to controls (p < 0.0001); and with combination of Bell or nosode 6cH and 30cH and oxacillin (p < 0.001). Bell 30cH and nosode 6cH and 30cH significantly decreased bacterial DNAse production (p < 0.001) and reduced red blood cell lysis. CONCLUSIONS: Cultures of MRSA treated with Belladonna or MRSA nosode exhibited reduced growth in vitro, reduced enzymatic activity and became more vulnerable to the action of the antibiotic oxacillin. Further studies are needed on the biomolecular basis of these effects.

Preparation, standardization and in vitro safety testing of Mycobacterium nosodes (Emtact- polyvalent nosode).

BACKGROUND: Most of the nosodes in the homeopathic pharmacopeia have been sourced from obscure pathological material over a century ago; of which no scientific documentation is available. METHOD: A method for preparation and standardization of univalent and polyvalent Mycobacterium nosodes (labeled as Emtact), using different strains of Mycobacterium tuberculosis was developed. The committee comprising microbiologists, scientist, pharmacist, homeopaths and clinicians had reviewed and approved the method of preparation of nosode. Preparation of the nosode was based on the reference in the Homeopathy Pharmacopoeia of India (HPI), group N-IV. Strains of M. tuberculosis viz. Standard strain H37Rv, multi-drug resistant (MDR) M. tuberculosis, Mycobacterium bovis (BCG vaccine) and Mycobacterium avium were identified, procured and documented. Twenty billion viable cells for each strain were taken for Original Stock Nosode (OSN). The original stock was prepared by suspending the microbial cells into water for injection (WFI) (1 ml). As per the Indian Pharmacopoeia (IP) monograph, sterility testing was done for different potencies. Polymerase Chain Reaction (PCR) was performed for 30c potency for detection of any DNA material of the source organisms. RESULT: A polyvalent (multi-strain) and univalent M. tuberculosis nosodes were prepared for research and clinical use. No growth of Mycobacterium was observed in any of the samples above 5c potency. The in-vitro testing for nosode (30c) was found to be free from any organism and DNA material. CONCLUSION: Mycobacterium nosodes sourced from individual strain and polyvalent Emtact nosode in vitro testing results found to be satisfactory for its handling and utilization. The nosode seems to be safe and may be tested further in vivo to explore its therapeutic application.

Estudio del efecto de dosis infinitesimales del nosode Streptococcinum sobre la actividad microbiana del Streptococcus ß-hemolítico del grupo a en un modelo in vitro / Study of the effect of infinitesimal doses of nosode Streptococcinum on the microbial activity of ß-hemolytic Streptococcus of group a in an in vitro model

El no reconocimiento de la homeopatía por parte de la «ciencia oficial¼, basándose en su aparente no plausibilidad biológica, (existencia de un mecanismo biológico plausible que explique la relación causa-efecto) no significa que los medicamentos homeopáticos no tengan un efecto. Sin embargo, incluso cuando en la literatura médica aparecen referidos efectos aceptables, entonces estos son relacionados con el azar, el efecto placebo o diseños metodológicos poco estrictos, atribuyendo dicha acción a factores como el azar, la no plausibilidad biológica, el efecto placebo, o a diseños metodológicos incorrectos. El presente estudio demuestra el efecto del nosode Streptococcinum sobre la actividad microbiana In Vitro del Streptococcus pyogenes a través de pruebas de sensibilidad microbiana, por las técnicas de dilución en caldo (método objetivo) y difusión en discos (método cualitativo), según las guías vigentes del NCCLS- (National Comittee for Clinical Laboratory Standars), referente actual del método empírico analítico (positivista) para estudios microbiológicos. Se importó la cepa Streptococcus pyogenes ATCC® 49399™ - KWIK-STIK™ - 2 KWIK STIK PASE 4 de Laboratorios Scharlau. (ITA). A partir de la misma y su posterior activación, se preparó el nosode Streptococcinum en las diluciones homeopáticas 6CH (no infinitesimal), y las infinitesimales 30CH, 200CH de la escala CH (Centesimal Hahnemanniana) y las diluciones 0/6, 0/30 y 0/60 LM de la escala cincuenta milesimal Hahnemaniana según la Farmacopea Homeopática Alemana (FHA). También, a partir de esta cepa, su activación y su calibración de curva de crecimiento a (λ=0.625nm), se montaron las pruebas de sensibilidad microbiana, según el método de difusión en disco con agar sangre y el método de dilución en caldo nutritivo con tripticasa de soja, cegando el experimento (método doble ciego), aleatorizando el experimento, e incluyendo controles (blanco) para mayor confiabilidad del ensayo. Se encontró que el nosode Streptococcinum en diluciones infinitesimales no presenta actividad antimicrobiana ni en el método de dilución en caldo ni en el método de difusión en disco, pero sí actividad promicrobiana en ambos métodos. Lo anterior se demostró cualitativamente (método de difusión en disco) a simple vista en todas las diluciones homeopáticas probadas, excepto en el control, y por espectrofotometría (cuantitativo), al alcanzarse la fase logarítmica una hora antes de lo esperado con la adición del nosode, al compararse con las curvas de calibración de crecimiento en las potencias 30CH, 200CH, 0/6, 0/30 y 0/60 LM, más no en la dilución 6CH, bajo la cual la curva de crecimiento se ajustó a la calibración. Lo anterior indica que el nosode Streptococcinum, a dosis infinitesimales, se comporta como un factor que acelera el crecimiento in vitro del S. pyogenes en el medio de cultivo, evidenciándose así una acción ponderal de las dosis infinitesimales, probablemente relacionada con la hormesis o con la ley de Arnold Shultz. Se requieren sin embargo nuevas pruebas confirmatorias. Se recomienda realizar estudios adicionales In vitro del efecto del Streptococcinum sobre células inmunológicas, y ensayos clínicos controlados para verificar la plausibilidad del efecto terapéutico del Streptococcinum.

Hepatitis C Nosode: The preparation and homeopathic pathogenetic trial.

BACKGROUND: A double blind, randomized placebo controlled homeopathic pathogenetic trial (proving) of Hepatitis C (Hep C) nosode was conducted with the aim to introduce the new nosode in homeopathic pharmacopeia. METHOD: Documentation included approval by Ethics Committee, Informed Consent Form, Laboratory investigations, safety and ethical measures. The volunteers were trained to write data in prescribed diaries and data were analyzed. A fifteen-step method was used in the preparation of Hep C nosode (genotype I and III), allowing future preparation of an identical nosode. 22 volunteers were entered, 15 received Hep C nosode in 30c potency, 7 received placebo, once a week for four weeks. RESULTS: The Hep C nosode was associated with qualitatively and quantitatively distinct symptoms, which can be applied in clinical practice. A significantly higher incidence of pathogenetic effect of homeopathic medicine compared to placebo was observed. Safety was documented. The nosode produced symptoms comparable with Hep C disease. CONCLUSION: An improved method of nosode preparation was used. A double blind, randomized placebo controlled pathogenetic trial of the Hep C nosode generated guiding symptoms, which may facilitate its prescription in practice. The nosode should be further explored for the treatment of immunologically mediated diseases, infections including Hep C, fibrotic pathology and chronic inflammatory disorders.

Avaliação do potencial genotóxico e mutagênico de um nosódio vivo obtido com o vírus Influenza A / Evaluation of the genotoxic and mutagenic potentials of a living nosode compounded with Influenza A virus

Introdução: O vírus da gripe tem sido responsável por doenças respiratórias contagiosas com altas taxas de mortalidade [1]. Algumas drogas tem sido usadas para tratar a gripe humana. No entanto, esses medicamentos causam muitos efeitos colaterais e induzem o aparecimento de cepas virais resistentes [2]. O impacto causado pelo vírus influenza tem motivado o desenvolvimento de novas abordagens para a prevenção e controle da influenza [3]. Portanto, um novo medicamento homeopático foi desenvolvido utilizando, como ponto de partida, o vírus influenza infecciosa [4]. Este pertence a um grupo chamado nosódios vivos [5]. No entanto, seus potenciais mutagênicos e genotóxicos, especialmente quando usado em diluições baixas, ainda não foram avaliados e é importante porque este bioterápico é preparado a partir de microorganismos vivos. Diferentes métodos podem ser usados para detectar efeitos mutagênicos e genotóxicos. Objetivos: Este estudo visa avaliar o potencial genotóxico e mutagênico do nosódio vivo do vírus influenza A, em diferentes potências homeopáticas.Metodologia: 1 ml de suspensão viral purificada foi diluída em 9 ml de água destilada estéril. Esta amostra foi submetida a 100 sucussões mecânicas (aproximadamente 3 Hz), usando o aparato Autic ® brasileira, originando a primeira diluição, chamada decimal (1x). 1 ml desta solução foi diluída em 9 ml de solvente e foi submetido a 100 sucussões, gerando o bioterápico 2x. Este procedimento foi repetido sucessivamente, de acordo com a Farmacopéia Homeopática Brasileira, para obter o bioterápico 30x [6]. Pela mesma técnica, a água foi preparada até a potência 30x, para ser utilizada como controle. Todas as amostras foram preparadas sob condições estéreis e assépticas, utilizando-se fluxo laminar, classe II, e foram armazenados em geladeira (8ºC). As amostras 1x, 6x, 12x, 18x 24x, 30x e 30x e água (controle do veículo) foram analisadas por: Induteste, avalia a capacidade dos agentes físicos ou químicos de promover a indução lisogênico como um reflexo dos danos nas moléculas de DNA em bactérias lisogênicas, e o teste de Ames, que utiliza linhagens indicadoras de Salmonella typhimurium, sensíveis a substâncias que podem induzir diferentes tipos de mutação. Resultados: Os resultados obtidos no Induteste não mostraram diminuição da fração de sobrevivência das bactérias utilizadas, e nenhum aumento na formação de indução lisogênica, em quaisquer potências testadas. O mesmo perfil foi obtido após o teste de Ames, com resultados semelhantes ao controle negativo. Conclusão: Conclui-se que nosódio vivo obtido com vírus Influenza A não é capaz de induzir danos no DNA de células procarióticas. Este resultado nos permite concluir que pacientes que usam este medicamento não tem efeitos colaterais relacionados com a mutagênese e genotoxicidade.(AU)

Background: The influenza virus has been responsible for contagious respiratory diseases with high mortality rates [1]. Some drugs have been used to treat human influenza. However, these drugs cause many common side effects and induce the appearance of resistant viral strains [2]. The impact caused by the influenza virus has motivated the development of new approaches for the prevention and control of influenza [3]. Therefore, a new homeopathic medicine was developed using, as a starting point, the infectious influenza virus [4]. This belongs to a group called living nosodes [5]. However, its mutagenic and genotoxic potentials, especially when used in low dilutions, has not yet been evaluated and it is important because this biotherapic is prepared from living microorganisms. Different methods can be used to detect mutagenic and genotoxicic effects. Aims: This study aims to evaluate the genotoxic and mutagenic potentials of influenza A living nosode at different homeopathic potencies. Methodology: 1 ml of purified viral suspension was diluted in 9 ml of sterile distilled water. This sample was submitted to 100 mechanical succussions (approximately 3 Hz), using Autic® Brazilian machine, originating the first dilution, named decimal (1x). 1 ml of this solution was diluted in 9 ml of solvent and was submitted to 100 sucussions, generating biotherapic 2x. This procedure was successively repeated, according to Brazilian Homeopathic Pharmacopoeia, to obtain the biotherapic 30x [6]. By the same technique, water vehicle was prepared until 30x potency to be used as control. All samples were prepared in sterile and under aseptic conditions, using laminar flow cabinet, class II, and were stored in the refrigerator (8ºC). The samples 1x, 6x, 12x, 18x, 24x and 30x and water 30x (vehicle control) were analysed by: the Inductest, which assesses the ability of physical or chemical agents to promote lysogenic induction as a reflection of damage in DNA molecules in lysogenic bacteria, and the Ames test, which uses indicator strains of Salmonella typhimurium, sensitive to substances that can induce different types of mutation. Results: The Inductest showed no decrease in the survival fraction of the bacteria used, and no increase in the formation of lysogenic induction, in any tested potency. The same profile was obtained after the Ames test, with similar results to negative control. Conclusion: We can conclude that this living nosode compounded with Influenza A virus is not able to induce DNA damage in prokaryotic cells. This result permits us to conclude that patients who use this medicine have no side effects related to mutagenesis and genotoxicity.(AU)

In vitro behavior of Mycoplasmagallisepticumlive-type nosode

As a step of a doctoral research project, in this study a live-type nosode was prepared from microorganism Mycoplasmagallisepticum strain R (ATCC 93-08/19610) according to Costa model and the rules by Brazilian Homeopathic Pharmacopoeia. Live nosode was tested in vitro to assess safety when used to immunize domestic fowl (Gallus gallus) against infection by this microorganism and to investigate its behavior under laboratory conditions. M. gallisepticum was not shown to grow in fluid (broth) and solid (plate) modified Frey medium with dilutions 11d, 12d, 20d and 30d. Inhibition halos about 2.0 mm were observed around paper disks impregnated with live-type nosode in microorganism-sown Petri dishes, whereas disks impregnated with conventional antibiotic oxytetracycline exhibited 8.0 mm inhibition halos. Protein assessment by Folin-Lowry method showed protein absence in dilutions 12d and 30d and neither microbial DNA traces were found in PCR assay in dilutions 12d, 20d and 30d.(AU)

Una etapa de un proyecto de doctorado, en este estudio fue preparado un nosode vivo del microorganismo Mycoplasmagallisepticumcepa R (ATCC 93-08/19610) según el modelo de Costa y las normas de la Farmacopea Homeopática Brasileña. El nosode vivo fue testeado in vitro para determinar su seguridad cuando utilizado para inmunizar aves domésticas (Gallus gallus) contra la infección por este microorganismo e investigar su conducta en condiciones de laboratorio. Fue observado que M. gallisepticum no creció en medio modificado de Frey líquido (caldo) y sólido (placa) con las diluciones 11d, 12d, 20d y 30d. Fueron observados halos de inhibición de aproximadamente 2,0 mm alrededor de discos de papel impregnados con el nosode vivo en placas de Petri sembradas con el microorganismo, mientras fueron observados halos de inhibición de 8,0 mm en los discos impregnados con el antibiótico convencional oxitetraciclina. La medición de proteínas mediante el método de Folin-Lowry evidenció ausencia de proteínas con las diluciones 12d y 30d y ausencia de vestigios de DNA microbiano por PCR con las diluciones 12d, 20d y 30d.(AU)

Como parte do experimento de uma tese de doutorado, um bioterápico do tipo nosódio vivo utilizando o microrganismo Mycoplasmagallisepticum estirpe R (ATCC 93-08/19610) foi preparado de acordo com o paradigma desenvolvido por Costa, observando as normas da Farmacopeia Homeopática Brasileira. O nosódio vivo foi testado in vitro com a finalidade de avaliar a segurança de sua utilização para imunizar galinhas domésticas (Gallus gallus) contra a infecção pelo microrganismo M.gallisepticum, e também conhecer seu comportamento sob condições de laboratório. Não houve crescimento de M. gallisepticum no cultivo em meio de Frey modificado líquido (caldo) e sólido (placa) das diluições 11d, 12d, 20d e 30d, enquanto que as diluições 1d e 10d mostraram crescimento do microrganismo. Foram observados halos de inibição de cerca de 2,0 mm em torno de discos de papel impregnados com o nosódio vivo em placas de Petri cultivadas com o microrganismo, enquanto os discos impregnados com o antimicrobiano convencional oxitetraciclina apresentaram halos de inibição de 8,0 mm. A dosagem de proteína pelo método de Folin-Lowry identificou a ausência de proteínas nas diluições 12d e 30d, assim como também não foram encontrados traços de DNA microbiano na prova de PCR para as diluições 12d, 20d e 30d.(AU)

In vitro behavior of Mycoplasmagallisepticumlive-type nosode / Comportamento in vitro do bioterápico tipo nosódio vivo mycoplasmagallisepticum / Conducta in vitro de nosodio vivo de mycoplasmagallisepticum

As a step of a doctoral research project, in this study a live-type nosode was prepared from microorganism Mycoplasmagallisepticum strain R (ATCC 93-08/19610) according to Costa model and the rules by Brazilian Homeopathic Pharmacopoeia. Live nosode was tested in vitro to assess safety when used to immunize domestic fowl (Gallus gallus) against infection by this microorganism and to investigate its behavior under laboratory conditions. M. gallisepticum was not shown to grow in fluid (broth) and solid (plate) modified Frey medium with dilutions 11d, 12d, 20d and 30d. Inhibition halos about 2.0 mm were observed around paper disks impregnated with live-type nosode in microorganism-sown Petri dishes, whereas disks impregnated with conventional antibiotic oxytetracycline exhibited 8.0 mm inhibition halos. Protein assessment by Folin-Lowry method showed protein absence in dilutions 12d and 30d and neither microbial DNA traces were found in PCR assay in dilutions 12d, 20d and 30d.(AU)

Una etapa de un proyecto de doctorado, en este estudio fue preparado un nosode vivo del microorganismo Mycoplasmagallisepticumcepa R (ATCC 93-08/19610) según el modelo de Costa y las normas de la Farmacopea Homeopática Brasileña. El nosode vivo fue testeado in vitro para determinar su seguridad cuando utilizado para inmunizar aves domésticas (Gallus gallus) contra la infección por este microorganismo e investigar su conducta en condiciones de laboratorio. Fue observado que M. gallisepticum no creció en medio modificado de Frey líquido (caldo) y sólido (placa) con las diluciones 11d, 12d, 20d y 30d. Fueron observados halos de inhibición de aproximadamente 2,0 mm alrededor de discos de papel impregnados con el nosode vivo en placas de Petri sembradas con el microorganismo, mientras fueron observados halos de inhibición de 8,0 mm en los discos impregnados con el antibiótico convencional oxitetraciclina. La medición de proteínas mediante el método de Folin-Lowry evidenció ausencia de proteínas con las diluciones 12d y 30d y ausencia de vestigios de DNA microbiano por PCR con las diluciones 12d, 20d y 30d.(AU)

Como parte do experimento de uma tese de doutorado, um bioterápico do tipo nosódio vivo utilizando o microrganismo Mycoplasmagallisepticum estirpe R (ATCC 93-08/19610) foi preparado de acordo com o paradigma desenvolvido por Costa, observando as normas da Farmacopeia Homeopática Brasileira. O nosódio vivo foi testado in vitro com a finalidade de avaliar a segurança de sua utilização para imunizar galinhas domésticas (Gallus gallus) contra a infecção pelo microrganismo M.gallisepticum, e também conhecer seu comportamento sob condições de laboratório. Não houve crescimento de M. gallisepticum no cultivo em meio de Frey modificado líquido (caldo) e sólido (placa) das diluições 11d, 12d, 20d e 30d, enquanto que as diluições 1d e 10d mostraram crescimento do microrganismo. Foram observados halos de inibição de cerca de 2,0 mm em torno de discos de papel impregnados com o nosódio vivo em placas de Petri cultivadas com o microrganismo, enquanto os discos impregnados com o antimicrobiano convencional oxitetraciclina apresentaram halos de inibição de 8,0 mm. A dosagem de proteína pelo método de Folin-Lowry identificou a ausência de proteínas nas diluições 12d e 30d, assim como também não foram encontrados traços de DNA microbiano na prova de PCR para as diluições 12d, 20d e 30d.(AU)

In vitro behavior of Mycoplasmagallisepticumlive-type nosode / Comportamento in vitro do bioterápico tipo nosódio vivo mycoplasmagallisepticum / Conducta in vitro de nosodio vivo de mycoplasmagallisepticum

As a step of a doctoral research project, in this study a live-type nosode was prepared from microorganism Mycoplasmagallisepticum strain R (ATCC 93-08/19610) according to Costa model and the rules by Brazilian Homeopathic Pharmacopoeia. Live nosode was tested in vitro to assess safety when used to immunize domestic fowl (Gallus gallus) against infection by this microorganism and to investigate its behavior under laboratory conditions. M. gallisepticum was not shown to grow in fluid (broth) and solid (plate) modified Frey medium with dilutions 11d, 12d, 20d and 30d. Inhibition halos about 2.0 mm were observed around paper disks impregnated with live-type nosode in microorganism-sown Petri dishes, whereas disks impregnated with conventional antibiotic oxytetracycline exhibited 8.0 mm inhibition halos. Protein assessment by Folin-Lowry method showed protein absence in dilutions 12d and 30d and neither microbial DNA traces were found in PCR assay in dilutions 12d, 20d and 30d.

Una etapa de un proyecto de doctorado, en este estudio fue preparado un nosode vivo del microorganismo Mycoplasmagallisepticumcepa R (ATCC 93-08/19610) según el modelo de Costa y las normas de la Farmacopea Homeopática Brasileña. El nosode vivo fue testeado in vitro para determinar su seguridad cuando utilizado para inmunizar aves domésticas (Gallus gallus) contra la infección por este microorganismo e investigar su conducta en condiciones de laboratorio. Fue observado que M. gallisepticum no creció en medio modificado de Frey líquido (caldo) y sólido (placa) con las diluciones 11d, 12d, 20d y 30d. Fueron observados halos de inhibición de aproximadamente 2,0 mm alrededor de discos de papel impregnados con el nosode vivo en placas de Petri sembradas con el microorganismo, mientras fueron observados halos de inhibición de 8,0 mm en los discos impregnados con el antibiótico convencional oxitetraciclina. La medición de proteínas mediante el método de Folin-Lowry evidenció ausencia de proteínas con las diluciones 12d y 30d y ausencia de vestigios de DNA microbiano por PCR con las diluciones 12d, 20d y 30d.

Como parte do experimento de uma tese de doutorado, um bioterápico do tipo nosódio vivo utilizando o microrganismo Mycoplasmagallisepticum estirpe R (ATCC 93-08/19610) foi preparado de acordo com o paradigma desenvolvido por Costa, observando as normas da Farmacopeia Homeopática Brasileira. O nosódio vivo foi testado in vitro com a finalidade de avaliar a segurança de sua utilização para imunizar galinhas domésticas (Gallus gallus) contra a infecção pelo microrganismo M.gallisepticum, e também conhecer seu comportamento sob condições de laboratório. Não houve crescimento de M. gallisepticum no cultivo em meio de Frey modificado líquido (caldo) e sólido (placa) das diluições 11d, 12d, 20d e 30d, enquanto que as diluições 1d e 10d mostraram crescimento do microrganismo. Foram observados halos de inibição de cerca de 2,0 mm em torno de discos de papel impregnados com o nosódio vivo em placas de Petri cultivadas com o microrganismo, enquanto os discos impregnados com o antimicrobiano convencional oxitetraciclina apresentaram halos de inibição de 8,0 mm. A dosagem de proteína pelo método de Folin-Lowry identificou a ausência de proteínas nas diluições 12d e 30d, assim como também não foram encontrados traços de DNA microbiano na prova de PCR para as diluições 12d, 20d e 30d.